Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.43 |
| ▸ | ACACA | Q13085 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | PPARD | Q03181 | 5/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476320 | 0.86 | ACACB (0.56) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL17050439 | 0.86 | ACACB (0.45) | ACACBACACACYP2C9CYP2C19PARP10 | |
| SCHEMBL17050442 | 0.84 | ACACB (0.43) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL17050444 | 0.83 | ACACB (0.44) | ACACBACACACYP2C9CYP2C19PARP10 | |
| SCHEMBL12476184 | 0.82 | ACACB (0.49) | ACACBACACACYP2C9CYP2C19PARP10 | |
| SCHEMBL12475958 | 0.81 | ACACB (0.38) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL12476150 | 0.80 | TRPA1 (0.42) | ACACBACACA | |
| SCHEMBL17050441 | 0.79 | ACACB (0.47) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL17050448 | 0.73 | ACACB (0.37) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL17050450 | 0.73 | HPGD (0.38) | ACACBACACACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | ACACB 2/4885ACACA 10/4885CYP2C9 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.